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Abstract
Background: Prenatal micronutrient combinations with high iron content are associated with high
rates of gastrointestinal symptoms. This coupled with nausea and vomiting of pregnancy results in
women often discontinuing their multivitamins.
A new prescription supplement (PregVit®) that separates iron from calcium in two tablets –
morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron
absorption when compared to another supplement containing (60 mg) of elemental iron
(Materna®). The objectives of this study were to compare tolerability and compliance with PregVit®
vs. a supplement with high iron content (Materna®), in pregnant women.
Methods: Randomized, crossover open labeled study in 135 pregnant women attending outpatient
clinics in Ontario and Quebec.
Results: Use of PregVit® was associated with a 30% reduction in constipation rate as compared to
Materna®. Both products demonstrated similar compliance rates.
Compliance of Materna® was negatively associated with the severity of nausea and vomiting of
pregnancy. No such correlation was found for PregVvit®.
Conclusion: PregVit®, a supplement with lower iron content (35 mg), has significantly decreased
constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron
content in multivitamin supplements is associated with adverse effects in pregnancy.
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Background
Prenatal micronutrient supplementation is indicated for
all pregnant women, because the recommended daily
allowances (RDA) for many vitamins and minerals are not
met during pregnancy with dietary sources alone [1,2].
Prior to 1990's, physicians typically commenced prenatal
micronutrients at the time of diagnosis of pregnancy.
However, proving the ability of folic acid supplementa-
tion to prevent neural tube defects, has led to the recom-
mendation to start prenatal micronutrient
supplementation when planning pregnancy [3,4]. A
recent analysis has further documented the importance of
micronutrient supplementation during pregnancy in pre-
venting malformations other than neural tube defects [5].
The findings are consistent with the notion that pericon-
ceptional multivitamin use, containing folic acid, reduces
the overall occurrence of birth defects by 15–33%, in
addition to the demonstrated reduction in neural tube
defects [6].
Typically, many prenatal supplements contain, among
other minerals, elemental iron at 50–60 mg, to prevent
pregnancy-induced anemia secondary to increasing fetal
needs. However, this level of iron content has been asso-
ciated adverse gastrointestinal effects, including nausea,
vomiting and constipation. The common occurrence of
nausea and vomiting of pregnancy (NVP) has further led
women to discontinue prenatal supplementation con-
taining these levels of iron [7].
A new prescription prenatal micronutrient supplement
PregVit® has recently been introduced into the Canadian
Market aiming to address these issues: PregVit®, taken
twice daily, contains less elemental iron (35 mg) than
many other prenatal supplements. Iron is incorporated in
the morning dose (Table 1). The evening dose of PregVit®
contains calcium, which is known to inhibit iron absorp-
tion from the gastrointestinal tract [8-11]. By separating
the two elements it was hypothesized that despite a lower
total iron dose – a similar systemic exposure to iron would
occur as with the other high iron prenatal supplements.
Moreover, PregVit® contains higher doses of vitamin C,
which is also known to facilitate iron absorption (Table
1).
A recent pharmacokinetic study has shown that the extent
of iron absorption with PregVit® (in terms of area under
the concentration-time curve) was similar to that of
Materna®, despite PregVit®containing only about half of
the iron dose [12].
The objective of the present study was to compare tolera-
bility and compliance with PregVit® and Materna® among
pregnant women.
Methods
Approval of the study protocol was obtained from the
local ethics committee at The Hospital for Sick Children,
in Toronto, Ontario, the North York General Hospital
(NYGH) in Toronto, Ontario and the Clinique de Gyné-
cologie-Obstétrique Pierre Boucher (CGOPB) in Quebec.
Appropriate sample size was determined to be one hun-
dred participants based on a desired effect size of 20%
fewer adverse effects with PregVit® versus Materna®.
Participants were eligible to enroll in the study if they
were pregnant and between 18 and 45 years of age. This
was a prospective, randomized, open labeled, cross over
study. Between June 2003 and November 2003, women
attending out patients obstetric clinics at NYGH and
CGOPB were invited to enroll in the study. During their
regular first obstetric appointment, participants reviewed
the protocol and signed an informed consent form. Partic-
ipating women were asked to complete a standardized
questionnaire recording demographic data, pregnancy
and, medical history, drug and vitamin use and informa-
tion on their normal bowel movements. Based on the
existence of NVP, participants were block-randomized to
receive either Materna® or PregVit® to be taken for one
month. The block randomization aimed at ensuring sim-
ilar numbers of women with NVP/no NVP receiving each
of the products first as NVP may affect compliance. They
were asked to keep a diary of any adverse event (e.g. con-
stipation, nausea and headache). The severity of their NVP
was monitored by the Pregnancy-Unique Questionnaire
of Emesis and nausea (PUQE) scores (Table 2) [13]. In
addition, changes in diet as well as the use of medications
and adherence to the study drug were recorded in the
diary. At the end of the month a pill count was conducted
to corroborate their diary reports. One month later, upon
their regular second follow-up visit, patients returned
their diaries and pill bottles. The women were then given
the alternative product and were asked to record the same
information in the diary for the following month. Upon
completion of the two month cross over, participants
were asked to return their diaries and supplement bottles
for a pill count.
Before starting the study, a pilot sample of 10 adult volun-
teers was tested for the feasibility of completing the diary.
They took PregVit® for one week followed by Materna® for
one week and were asked to fill out the diary. Minor
changes were made to the diary based on comments col-
lected during the pilot phase.
Sample size and statistical analysis
The primary end point of interest was the mean rate of
adverse events in the two study arms, including decreased
compliance. The mean compliance based on pill counts
and diary reports were compared between the two studyBMC Pregnancy and Childbirth 2006, 6:10 http://www.biomedcentral.com/1471-2393/6/10
Page 3 of 6
(page number not for citation purposes)
arms by paired Student's t  test or signed rank test, as
appropriate. Other variables such as mean days of experi-
encing adverse drug event (ADE), nausea, constipation
and other ADE, excluding nausea and constipation,
(labeled as other), were also compared using the same sta-
tistical tests, as appropriate. The incidence of nausea and
noncompliance due to constipation were compared
between the two groups using chi-square. All statistical
tests were performed using Sigmastat® statistical software,
Version 2.03 (SPSS Inc, Chicago, IL). Subsequently, mul-
tilinear regression analysis was conducted to elucidate
determinants that affected compliance rate with the study
drugs. Determinants of compliance were chosen based on
factors showing significant in recent literature [14-17].
Rates of constipation were the primary end point of inter-
est, as high iron content is known to induce constipation.
Sample size of 100 was calculated to show a 33% decrease
in rate of constipation (from 30% to 20%) at power of
80% and alpha of 5%.
Results
A total of 109 patients from NYGH consented to enroll in
the study. Of these 109 patients, 37 patients with NVP and
45 Non NVP patients completed both arms of the study,
totaling 82 patients (75.2%). Of 100 patients agreed to
enroll in the study at the CGOPB (35 NVP and 65 Non
NVP), 18 NVP patients and 38 Non NVP patients, for a
total of 56 patients, completed the study (56%). Hence, a
total of 138 patients completed the study and were
included in the data analysis. The mean gestational age at
the start was 8 ± 2 weeks. There was identical gestational
age at start in the two arms. The women who dropped out
from the study almost entirely due to the fact that they did
not return for follow-up or did not fill out diaries on
returning the pill bottles. They did not differ from those
who completed the study in any characteristic collected
Table 1: Composition of two prenatal supplements and Recommended Dietary Allowance (RDA) values12
Component PregVit® Materna® *** Recommended dietary 
allowance (RDA)
a.m. tablet**
Vit. Aψ 2700 IU (β-Carotene) 1500 IU (β-Carotene) 1500 IU (acetate) 750–770 µg retinol
Vit. Eξ 30 IU 30 IU 15 mg
Vit. C 120 mg 100 mg 80–85 mg
Vit. B1 (thiamin) 3 mg 3 mg 1.4 mg
Vit. B2 (riboflavin) 3.4 mg 3.4 mg 1.4 mg
Niacinamide 20 mg 20 mg 18 mg
Vit. B6 10 mg 10 mg 1.9 mg
Pantothenic acid 
(calcium pantothenate)
5 mg 10 mg 6 mg*
Magnesium 50 mg 50 mg 350–400 mg
Iodine 0.15 mg 0.15 mg 0.22 mg
Iron 35 mg (as fumarate) 60 mg (as fumarate) 27 mg
Copper 2 mg 2 mg 1 mg
Zinc 15 mg 25 mg 11–12 mg
p.m. tablet**
Folic Acid 1.1 mg 1 mg 0.6 mg
Vit. B12 
(cyanocaobalamin)
12 µg 12 µg2 . 6   µg
Vit. D (cholecalciferol)ε 250 IU 250 IU 5 µg*
Calcium 300 mg 250 mg 1000–1300 mg*
Biotin 0 30 µg-
Chromium 0 25 µg 29–30 µg*
Manganese 0 5 mg 2 mg*
Molybdenum 0 25 µg 50 µg
Selenium 0 25 µg 60 µg
Pill Size Small large
* Adequate Intake
** Applies only to PregVit®
ψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 µg retinol (750 µg of retinol is 2,500 IU of retinol)
2 µg of supplemental β-carotene is equivalent to 1 µg retinol 3 (page 92 & 565)
ξVIT E – 1 International Unite (IU) is equivalent to 0.67 µg of α-tocopherol (15 mg is equivalent to 22,388 IU)
However, different conversion factors are used for different forms of vitamin E
εVIT D – 1 IU is equivalent to 0.025 µg of cholecalciferol (5 µg is equivalent to 200 IU)
***Please note: Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.BMC Pregnancy and Childbirth 2006, 6:10 http://www.biomedcentral.com/1471-2393/6/10
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and reported by us. Among those who did not complete
the study, there was no higher prevalence to any of the
two arms (e.g., PregVit® vs Materna®).
There was a significantly higher incidence of reported con-
stipation, as well as average duration of constipation
when taking Materna® as compared to PregVit® (Table 3).
Multivariate linear regression was conducted to elucidate
factors that independently affected compliance. The fac-
tors tested included: age, education, province, marital sta-
tus, weight, NVP severity, any substance used such as illicit
drugs and multivitamin supplement (which multivitamin
they started the trial with). These factors have been shown
in previous studies to affect compliance [18]. The depend-
ent variable used was reported compliance. Including all
138 patients, using both arms of the study, no variable sig-
nificantly predicted compliance rate (Table 4).
Finally, multiple linear regression with patients and their
reported compliance while taking Materna® revealed that
marital status and NVP severity predicted their reported
compliance; single motherhood predicted higher compli-
ance rates whereas more severe NVP predicted a lower
compliance rate (Table 5). No such correlation was
detected for PregVit®.
Discussion
The results of this study demonstrate that pregnant
women may experience less constipation when taking
PregVit®. These results are likely attributed to the lower
iron dose contained in PregVit® relative to Materna® (35
mg and 60 mg, respectively) (Table 1). The other differ-
ences in micronutrient content between the two prepara-
tions are not known to affect constipation rate. It should
be noted that since the completion of this study the dose
of iron in Materna® has been reduced to 27 mg. The refor-
mulated Materna® has the same levels of calcium, manga-
nese and zinc as before. Thus, with lower vitamin C
Table 2: The PUQE Score (12). Patients were asked to circle the appropriate box next to the three symptoms of nausea and vomiting 
of pregnancy (NVP). The score of each box is represented by the top row. The total score is calculated and determines the severity of 
NVP14. A score of 3 to 6 represents Mild NVP. A score of 7 to 12 indicates Moderate NVP. Finally a score of 13 and greater represents 
Severe NVP.
12345
QUESTION 1In the 
last 12 hours, how 
long have you felt 
nauseated or sick 
at your stomach?
Not at all 1 hour or less 2–3 hours 4–6 hours More than 6 hours 
(Please specify 
number of hours)
QUESTION 2In the 
last 12 hours, have 
you vomited or 
thrown up?
I did not throw up 1–2 times 3–4 times 5–6 times 7 or more times 
(Please specify 
number of times)
QUESTION 3In the 
last 12 hours, how 
many times have you 
had retching or dry 
heaves without 
bringing anything up?
No Time 1–2 times 3–4 times 5–6 times 7 or more (Please 
specify number of 
times)
Table 3: Overall study results, comparing Pregvit® (low iron) to Materna® (high iron) over a month administration in a cross-over 
design.
(n)* PregVit® (SD) Materna® (SD) p value
Pill Count (% of 100%) 78 87.7 ± 20 90.9 ± 17 0.11
Reported Compliance 
(%)
138 90.4 ± 18 92.4 ± 15 0.42
Adverse events (%) 138 17.6 ± .24 20.3 ± 24 0.14
Nausea (%) 138 9.3 ± 19 10.1 ± 18 0.71
Constipation time 
length (%)
138 3.1 ± 8 4.7 ± 11 0.05
Other adverse events 138 (n) 10.4 ± 21 99.9 ± 20 0.95
Nausea rate (%) 138 41.3 (57/81) 45.7 (63/75) 0.54
Constipation Rate (%) 138 22.5% (31/107) 34.8% (48/90) 0.03
n represents the number of patients (out of 138) who completed any particular item.BMC Pregnancy and Childbirth 2006, 6:10 http://www.biomedcentral.com/1471-2393/6/10
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content than PregVit®, it is possible that the systemic
absorption of iron of Materna® may be subtherapeutic14.
Moreover, studies have suggested an antagonistic relation-
ship between iron and zinc and manganese, in which zinc
and manganese reduce the positive effects of iron supple-
mentation and vice versa [19,21].
It is likely that the higher dose of zinc, found in Materna®
versus PregVit® plus manganese, (which is not included in
PregVit®) all interfere with the absorption of iron. A 1993
study(16) found that supplementation with a low daily
dose (18 mg) of iron given in a prenatal supplement
together with inhibitive minerals was not sufficient to
cover the iron needs of most pregnant women. Impor-
tantly, many prenatal supplements currently available still
contain 50–60 mg of elemental iron.
Two methods were used to estimate compliance: Patients'
reported compliance and pill count. Using these meas-
ures, compliance was found to be similar for both prod-
ucts. The similar compliance may be a reflection of better
tolerability with PregVit®, being partially offset by the
need to take this supplement twice daily, as compared to
once daily with Materna®.
Of potential clinical importance, the multivariate analysis
revealed that compliance with Materna® was negatively
related to the severity of nausea and vomiting of preg-
nancy. This agrees with a recent study documenting that
the severity of morning sickness adversely affects use of
Materna® (6). This may be explained also by a substan-
tially larger pill size as compared to PregVit®, in addition
to the direct effect of iron. These findings suggest that
PregVit® may confer an advantage to women suffering
from NVP due to both higher tolerability because of lower
iron content and a smaller tablet size. Because NVP can
very from slight food aversion to hyperemesis gravi-
darum, we used a validated tool that quantifies the sever-
ity of NVP (Table 2).
Potential weaknesses of this study are that the participa-
tion in this cross over protocol may act to improve com-
pliance among participant, and that, similar to other
randomized controlled studies, the demonstrated high
compliance figures do not reflect those of naturalistic
"real life" drug administration. We experienced a rela-
tively high drop out rate. This did not reflect failure to take
the two products but rather lack of motivation of healthy
pregnant women to participate in this type of intensive
protocol including daily diaries and returning pills. How-
ever, because each woman served as her own control, the
attrition does not bias the results. The women who
dropped out were not different in their characteristics
from those who completed the protocol. Importantly,
Table 4: Multiple linear regression of factors affecting compliance in both treatment arms.
Independent Variable Coefficient Standard Error p value
Age 0.00 0.002 0.43
Education -0.01 0.011 0.58
Province 0.04 0.026 0.17
Marital Status -0.02 0.028 0.43
Weight 0.00 0.000 0.14
NVP Severity -0.02 0.012 0.08
Substance use* 0.00 0.036 0.79
Multivitamin Supplement -0.01 0.019 0.75
* alcohol, tobacco or illicit drugs
Table 5: Multiple linear regression of compliance in patients while taking Materna®
Independent Variable Coefficient Standard Error p value
Age 0.00 0.002 0.73
Education -0.02 0.014 0.09
Province 0.03 0.031 0.37
Race 0.02 0.010 0.11
Marital Status -0.08 0.034 0.02
Weight 0.00 0.000 0.14
NVP Severity* -0.05 0.014 0.002
Substance** -0.06 0.044 0.20
* More severe NVP was associated with significantly lower compliance. No such effect was found with Pregvit®, which is a substantially smaller 
tablet, containing much lower iron content.
** alcohol, tobacco or illicit drugsBMC Pregnancy and Childbirth 2006, 6:10 http://www.biomedcentral.com/1471-2393/6/10
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because compliance rate was an important endpoint we
refrained from contacting the women to remind them of
their participation, an act that could artificially affect com-
pliance, with the medications. Previous studies also
reported on diarrhea occurring with micronutrients, how-
ever, in our study the occurrence of diarrhea was very rare
and not different between the two study interventions.
Yet, this study, comparing tolerability and compliance
rates between two prenatal micronutrient supplements
different in their iron content and administration sched-
ule, has identified several determinants of potential clini-
cal significance, which may affect pregnant women's
adherence to micronutrient supplementation.
A major problem in primary prevention of congenital
anomalies by folic acid or folic acid containing micronu-
trients is the need to commence supplementation precon-
ceptionally. There is a serious and urgent need to educate
potential parents to start such supplementation before
pregnancy is confirmed.
Conclusion
PregVit®, a supplement with lower iron content (35 mg),
has significantly decreased constipation rates as compared
to 60 mg iron- Materna and has similar compliance rates.
High iron content in multivitamin supplements is associ-
ated with adverse effects in pregnancy.
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